Share:
APPROVAL ALLOWS
RESOLUTE 2.0 TEST KIT TO BE USED WITH A VARIETY OF TESTING METHODS – INCLUDING DEEP-THROAT SALIVA, OROPHARYNGEAL/MIDDLE TURBINATE AND NASOPHARYNGEAL TEST SWABS
RESOLUTE 2.0 WILL BE USED AT SINGAPORE CHANGI AIRPORT WITH THE NEW ON-SITE ADDITION OF A COVID-19 TESTING LAB IN 2021.
Advanced MedTech Holdings (AMTH), a global medical technology leader headquartered in Singapore, announced today that the RESOLUTE 2.0 test kit has become the first RT-PCR COVID-19 test to be authorised by Singapore s Health Sciences Authority (HSA) for deep-throat saliva (DTS) SARS-CoV-2 testing.
The clinical performance of DTS is supported by clinical studies involving the Diagnostics Development (DxD) Hub hosted by the Agency for Science, Technology and Research (A STAR); Temasek Foundation; Changi General Hospital (CGH); DSO National Laboratories (DSO); and Woodlands Health Campus (WHC). The tests conducted on DTS specimens were able to accurately identify all the known
Singapore s Covid-19 candidate,
ARCT-021, is also an mRNA vaccine. It is developed by Arcturus Therapeutics in collaboration with scientists from the Duke-NUS Medical School.
Because mRNA is easily degraded, Pfizer wraps its BNT162b2 mRNA vaccine in oily bubbles made of lipid nanoparticles so that the vaccine can reach its target in the body.
Have the vaccines been effective?
Data from trials have shown that some of the vaccines highlighted above are somewhat effective, though some results are more (or less) conclusive and convincing than others.
Pfizer and Moderna have reported efficacy rates of between 90 and 95 per cent from their Phase 3 trials.